Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾Æ¿¡¼­ ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó À§Àå°ü¿°ÀÇ ÀÓ»ó¾ç»ó°ú Ç×»ýÁ¦ ³»¼º·ü¿¡ ´ëÇÑ ¿¬±¸ Non-typhoidal Salmonella Gastroenteritis in Childhood: Clinical Features and Antibiotics Resistance

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2002³â 5±Ç 2È£ p.150 ~ 157
³ª¼Ò¿µ, ±èº´Âù, ¾çÇý¶õ, Á¤¼öÁø, ÀÌ°æÈÆ, °íÀ缺, ÀÌȯÁ¾, ±èÀÇÁ¾, ¼­Á¤±â,
¼Ò¼Ó »ó¼¼Á¤º¸
³ª¼Ò¿µ ( Na So-Young ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

±èº´Âù ( Kim Beyong-Chan ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¾çÇý¶õ ( Yang Hye-Ran ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
Á¤¼öÁø ( Chung Su-Jin ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌ°æÈÆ ( Lee Kyung-Hun ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
°íÀ缺 ( Ko Jae-Sung ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌȯÁ¾ ( Lee Hoan-Jong ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±èÀÇÁ¾ ( Kim Eui-Chong ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
¼­Á¤±â ( Seo Jeong-Kee ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

¸ñÀû: ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó±ÕÀº ¼¼±Õ¼º À§Àå°ü¿° ¹× Àå¿­ µîÀ» ÀÏÀ¸Å°´Â Áß¿äÇÑ ¿øÀαÕÀ¸·Î Àü ¼¼°èÀûÀ¸·Î ¹ß»ý·üÀÌ Áõ°¡ÇÒ »Ó ¾Æ´Ï¶ó Ç×»ýÁ¦¿¡ ´ëÇÑ ´ÙÁ¦³»¼º·üµµ Áõ°¡ÇÏ´Â Ãß¼¼ÀÌ´Ù. ±×·¯³ª ÀÌ¿¡ ´ëÇÑ ¼Ò¾Æ¿¡¼­ÀÇ ¿¬±¸ º¸°í´Â ¸¹Áö ¾Ê¾Æ ÀúÀÚµéÀº
ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó À§Àå°ü¿°ÀÇ ÀÓ»ó ¾ç»ó°ú Ç×»ýÁ¦ ³»¼º·ü µî¿¡ ´ëÇÏ¿© ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: 2000³â 1¿ùºÎÅÍ 2002³â 6¿ù±îÁö ¼­¿ï´ëÇб³ ¾î¸°À̺´¿ø¿¡ ³»¿øÇÏ¿© ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó À§Àå°ü¿°À¸·Î Áø´Ü¹ÞÀº ȯ¾Æ¸¦ ´ë»óÀ¸·Î ÀÓ»ó¾ç»ó, Ç×»ýÁ¦ ³»¼º·ü ¹× ¸é¿ª »óÅ¿¡ µû¸¥ ³»¼º·ü°ú ´ÙÁ¦³»¼º·ü µîÀ» Á¶»çÇÏ¿´´Ù.

°á°ú: ´ëº¯ °Ë»ç»ó ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó±ÕÀÌ ºÐ¸®µÈ 99·Ê Áß, ³²¾Æ°¡ 66·Ê ¿©¾Æ°¡ 33·Ê¿´´Ù. 2¼¼ ÀÌ»ó 3¼¼ ¹Ì¸¸ÀÌ 23·Ê·Î °¡Àå ¸¹¾ÒÀ¸¸ç 5¼¼ ¹Ì¸¸¿¡¼­ ¹ß»ýÇÑ °æ¿ì°¡ ÀüüÀÇ 71%¿¡ ÇØ´çÇÏ¿´°í Æò±Õ ¿¬·ÉÀº 4.0¼¼¿´´Ù. 25·Ê´Â Ç×¾Ï È­Çпä¹ýÀ̳ª ½ºÅ×·ÎÀÌµå ¹× ¸é¿ª ¾ïÁ¦Á¦ Ä¡·á µîÀ¸·Î ¸é¿ª ±â´ÉÀÌ ÀúÇÏµÈ È¯ÀÚ¿´´Ù. Ç÷û±º Áß D±ºÀÌ 65·Ê·Î °¡Àå ¸¹¾Ò°í B±ºÀÌ 16·Ê, C±º°ú E±ºÀÌ °¢°¢ 8·Ê¿´´Ù. 3·Ê¿¡¼­ ±ÕÇ÷ÁõÀÌ µ¿¹ÝµÇ¾ú´Ù. Ç×»ýÁ¦¿¡ ´ëÇÑ ³»¼º·üÀ» º¸¸é ampicillin¿¡ 31%, chloramphenicol¿¡ 12%, TMP-SMX¿¡ 20%, cefotaxime¿¡ 11%, cefixime¿¡ 8%ÀÇ ³»¼º·üÀ» º¸¿´À¸¸ç ciprofloxacinÀº ¸ðµç±ÕÁÖ¿¡¼­ °¨¼ö¼ºÀ» º¸¿´´Ù. Cefotaxime°ú cefixime¿¡ ´ëÇÑ ³»¼º·üÀº ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ È¯¾Æ±º¿¡¼­ °¢°¢ 24%, 14.3%·Î Á¤»ó±º¿¡¼­ÀÇ 6.8%, 5.6%º¸´Ù À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p£¼0.05). ¿¬·Éº°(5¼¼ ¹Ì¸¸ vs 5¼¼ ÀÌ»ó), Ç÷û±ºº°(D±º vs ºñD±º) ³»¼º·üÀÇ Â÷ÀÌ´Â ¾ø¾ú´Ù. ÇÑÆí 3°¡Áö ÀÌ»óÀÇ Ç×»ýÁ¦¿¡ ³»¼ºÀ» º¸ÀÌ´Â ´ÙÁ¦³»¼º±ÕÀº 11·Ê¿¡¼­ µ¿Á¤µÇ¾ú°í, ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ È¯¾Æ±º¿¡¼­ÀÇ µ¿Á¤·üÀÌ 24%·Î Á¤»ó±º¿¡¼­ÀÇ µ¿Á¤·üÀÎ 6.8%º¸´Ù À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p£¼0.05).

°á·Ð: ºñÀåƼǪ½º¼º »ì¸ð³Ú¶ó À§Àå°ü¿°ÀÎ ¼Ò¾Æ ȯÀÚ¿¡¼­ Ç×»ýÁ¦ Ä¡·á¸¦ ÇØ¾ß ÇÏ´Â °æ¿ì¿¡, ¼Ò¾Æ¿¡¼­ ¾ÈÁ¤¼ºÀÌ È®¸³µÇÁö ¾ÊÀº quinoloneÀ» Á¦¿ÜÇÑ´Ù¸é 3¼¼´ë cephalosporinÀ» 1Â÷ ¼±ÅÃÁ¦·Î °í·ÁÇÒ ¼ö ÀÖ´Ù. ±×·¯³ª º» ¿¬±¸¿¡¼­Ã³·³ ¸é¿ª ±â´ÉÀÌ ÀúÇϵÈ
ȯÀÚ¿¡¼­´Â cefotaxime°ú cefixime¿¡ ´ëÇÑ ³»¼º·ü°ú ´ÙÁ¦³»¼º·üÀÌ À¯ÀÇÇÏ°Ô ³ôÀ¸¹Ç·Î ÀûÀýÇÑ Ç×»ýÁ¦ ¼±Åÿ¡ ÁÖÀÇÇØ¾ß ÇÒ °ÍÀ̸ç ÇâÈÄ ÀÌ¿¡ ´ëÇÑ ¿¬±¸°¡ ´õ ÇÊ¿äÇϸ®¶ó »ý°¢µÈ´Ù.

Purpose: As the incidence of non-typhoidal salmonella strains resistant to antibiotics has been increased, we attempted to investigate clinical aspects of non-typhoidal salmonella gastroenteritis and antibiotics resistance.

Methods: From January 2000 to June 2002, 99 children with positive stool culture of non-typhoidal salmonella were studied about clinical features, the incidence of antibiotics and multi-drug resistance and the difference of incidence of antibiotics resistance according to immune status.

Results: There were 66 males and 33 females. The majority of them were under 5 years of age (71%). 25 children were immunocompromised due to chemotherapy, steroid or immunosuppressive treatment. Serogroup D was the most common isolates (65%) followed by B (16%), C (8%) and E (8%). Resistance rate of 30% to ampicillin, 12% to chloramphenicol, 20% to trimethoprim- sulfamethoxazole (TMP-SMX), 11% to cefotaxime and 8% to cefixime were obtained. All isolates were susceptible to ciprofloxacine. Resistance rate to cefotaxime and cefixime in immunocompromised patients was 24% and 14.3% respectively, which were significantly higher compared to that in immunocompetent patients (6.8%, 5.6%, p£¼0.05). 11 isolates were resistant to three or more antibiotics. The incidence of multi-drug resistant isolates was significantly higher in immunocompromised patients (24%) than that of immunocompetent patients (6.8%).

Conclusion: Because of the high prevalence of non-typhoidal salmonella strains resistant to ampicillin, chloramphenicol and TMP-SMX, third-generation cephalosporin might be the treatment of choice in non-typhoidal salmonella gastroenteritis. In particular, antibiotics should be carefully selected in immunocompromised patients because non-typhoidal salmonellas from them showed the higher incidence of antibiotic resistance and multi-drug resistance.

Å°¿öµå

Non-typhoidal salmonella gastroenteritis;Antibiotics resistance

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS